LONDON (Thomson Financial) - Hutchison China Meditech Ltd said its Hutchison MediPharma unit plans to start a phase IIb trial of HMPL-004, its anti-inflammatory drug candidate, after receiving approval from the US Food and Drug Administration.
The company said the tests will be conducted on patients with mild-to-moderate ulcerative colitis, a form of inflammatory bowel disease.
Separately, Hutchison China Meditech said HMPL-004 is in phase II clinical trial in the US for Crohn's disease, and expects to report the results by late next year. tfn.newsdesk@thomson.com ndi/bsu/wj COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2007 AFX News
